Shopping Cart 0
Cart Subtotal
USD 0

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Pipeline Review, H2 2017

Summary

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 20 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 13 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Infectious Disease and Hematological Disorders which include indications Breast Cancer, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Graft Versus Host Disease (GVHD), Hepatitis B, Hepatocellular Carcinoma, Lymphoma, Metastatic Melanoma, B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus Infections, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.

The latest report CD40 Ligand-Pipeline Review, H2 2017, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects

The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Overview 7

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Companies Involved in Therapeutics Development 24

Bristol-Myers Squibb Company 24

eTheRNA Immunotherapies NV 24

Juno Therapeutics Inc 25

MedImmune LLC 25

Memgen LLC 26

Multimeric Biotherapeutics Inc 26

Sanofi 26

Tessa Therapeutics Pte Ltd 27

TILT Biotherapeutics Ltd 27

UCB SA 27

XL-protein GmbH 28

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Drug Profiles 29

Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

dapirolizumab pegol-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Delta-24-RGDOX-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Dendritic Cell Therapy + TILT-234-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ECI-006-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

hepatitis B vaccine-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

INX-021-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

ISF-35-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

letolizumab-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

LOAd-700-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

MEDI-4920-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

MegaCD40L-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

NJA-730-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TDI-28-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

TDI-846-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

TT-16-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

UltraCD40L-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Vaccine to Target CD40L and GM-CSF for Oncology-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

XL-050-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Dormant Products 54

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Product Development Milestones 56

Featured News & Press Releases 56

Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016) 56

Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma 56

Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS 57

Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting 57

Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011 58

Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 58

Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia 59

Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy 60

Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting 60

Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting 60

Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia 61

Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia 61

Oct 21, 1999: Biogen Announces Halt In Several Trials Of Anti-CD40 Ligand Monoclonal Antibody 61

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Top 10 Molecule Types, H2 2017 22

Number of Products by Stage and Top 10 Molecule Types, H2 2017 22


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 23

Pipeline by Bristol-Myers Squibb Company, H2 2017 24

Pipeline by eTheRNA Immunotherapies NV, H2 2017 25

Pipeline by Juno Therapeutics Inc, H2 2017 25

Pipeline by MedImmune LLC, H2 2017 26

Pipeline by Memgen LLC, H2 2017 26

Pipeline by Multimeric Biotherapeutics Inc, H2 2017 26

Pipeline by Sanofi, H2 2017 27

Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 27

Pipeline by TILT Biotherapeutics Ltd, H2 2017 27

Pipeline by UCB SA, H2 2017 28

Pipeline by XL-protein GmbH, H2 2017 28

Dormant Products, H2 2017 54

Dormant Products, H2 2017 (Contd..1), H2 2017 55

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Therapeutic Products under Development, Key Players in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Therapeutics, CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Pipeline Overview, CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Pipeline, CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Pipeline Assessment


Companies

Bristol-Myers Squibb Company

eTheRNA Immunotherapies NV

Juno Therapeutics Inc

MedImmune LLC

Memgen LLC

Multimeric Biotherapeutics Inc

Sanofi

Tessa Therapeutics Pte Ltd

TILT Biotherapeutics Ltd

UCB SA

XL-protein GmbH